Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D62LKT
|
|||
| Drug Name |
BI 836880
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Neoplasm [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | |
| Wet age-related macular degeneration [ICD-11: 9B78.3Z; ICD-10: H35.31] | Phase 1 | [2] | ||
| Company |
Boehringer Ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin-2 (ANGPT2) | Target Info | Blocker | [3] |
| Vascular endothelial growth factor (VEGF) | Target Info | Blocker | [3] | |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | Angiopoietin receptor Tie2-mediated signaling | |||
| Reactome | Tie2 Signaling | |||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03972150) A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03861234) A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.